Treatment with anti-CDK6 inhibitor palbociclib in TMZ-resistant GBM PDX mouse model led to anti-tumorigenic phenotypes including reduced SNHG12 transcript levels [96]. This evidence concerns the gene SNHG12 and glioblastoma.